Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

Penmenvy, GSK’s pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating, uncomplicated urinary tract infection were approved in the United States in the first quarter of ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 sales.

"The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women," said GSK's chief scientific offer Tony Wood, pointing out that around 16 million women in the ...

GSK continues to make strong progress ... Along with the recent approvals for Penmenvy and Blujepa, we continue to expect FDA approvals for Nucala COPD imminently, Blenrep in July, and depemokimab ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

London's FTSE 100 was set to finish lower on Wednesday for the first time in four weeks, with heavyweight names in the pharmaceutical and telecoms sectors providing a drag.

Focusing on a new antibiotic for UTIs, which haven’t had a novel therapy in decades, was intentional, Walmsley says. Half of ...